[go: up one dir, main page]

WO2008144507A3 - Spirooxindole inhibitors of aurora kinase - Google Patents

Spirooxindole inhibitors of aurora kinase Download PDF

Info

Publication number
WO2008144507A3
WO2008144507A3 PCT/US2008/063893 US2008063893W WO2008144507A3 WO 2008144507 A3 WO2008144507 A3 WO 2008144507A3 US 2008063893 W US2008063893 W US 2008063893W WO 2008144507 A3 WO2008144507 A3 WO 2008144507A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
spirooxindole
compounds
aurora
kinases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/063893
Other languages
French (fr)
Other versions
WO2008144507A2 (en
Inventor
Timothy A Lewis
Karl Munger
Peter M Howley
Angela N Koehler
Hiroyuki Hayakawa
Christopher S Neumann
Stuart L Schreiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of WO2008144507A2 publication Critical patent/WO2008144507A2/en
Publication of WO2008144507A3 publication Critical patent/WO2008144507A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Aurora kinases have been found to be overexpressed in many tumors including breast, colon, and pancreatic cancers. The present invention provides novel inhibitors and/or binders of Aurora kinases. Certain of the spirooxindole compounds are specific inhibitors or binders of Aurora A, B, or C kinases. The compounds are useful in both the diagnosis and treatment of proliferative diseases such as cancer. Pharmaceutical compositions and method of using the compounds to treat proliferative diseases are also provided.
PCT/US2008/063893 2007-05-16 2008-05-16 Spirooxindole inhibitors of aurora kinase Ceased WO2008144507A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93836207P 2007-05-16 2007-05-16
US60/938,362 2007-05-16

Publications (2)

Publication Number Publication Date
WO2008144507A2 WO2008144507A2 (en) 2008-11-27
WO2008144507A3 true WO2008144507A3 (en) 2009-05-14

Family

ID=39708725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/063893 Ceased WO2008144507A2 (en) 2007-05-16 2008-05-16 Spirooxindole inhibitors of aurora kinase

Country Status (1)

Country Link
WO (1) WO2008144507A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263547B2 (en) 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
CN106008532B (en) * 2016-07-20 2019-06-07 贵州大学 Alcoxyl yl pyrimidines splice 3- pyrroles's loop coil oxoindole derivative and preparation method and application
US11976084B2 (en) 2020-11-23 2024-05-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2022235605A1 (en) 2021-05-04 2022-11-10 Enanta Pharmaceuticals, Inc. Novel macrocyclic antiviral agents
US12398147B2 (en) 2021-05-11 2025-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023091561A1 (en) * 2021-11-18 2023-05-25 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
WO2023196307A1 (en) 2022-04-05 2023-10-12 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091646A2 (en) * 2005-02-22 2006-08-31 The Regents Of The University Of Michigan Small molecule inhibitors of mdm2 and uses thereof
WO2007047579A2 (en) * 2005-10-14 2007-04-26 Virginia Tech Intellectual Properties, Inc. A novel therapeutic target for protozoal diseases
WO2008027990A1 (en) * 2006-08-29 2008-03-06 Trustees Of Boston University Therapeutic methods using wrn binding molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091646A2 (en) * 2005-02-22 2006-08-31 The Regents Of The University Of Michigan Small molecule inhibitors of mdm2 and uses thereof
WO2007047579A2 (en) * 2005-10-14 2007-04-26 Virginia Tech Intellectual Properties, Inc. A novel therapeutic target for protozoal diseases
WO2008027990A1 (en) * 2006-08-29 2008-03-06 Trustees Of Boston University Therapeutic methods using wrn binding molecules

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHRIS V. GALLIFORD ET AL: "A highly diastereoselective, catalytic three-component assembly reaction for the synthesis of spiropyrrolidinyloxindoles", CHEMICAL COMMUNICATIONS, vol. 6, 2007, pages 631 - 633, XP002517188 *
CHUO CHEN ET AL: "Convergent diversity-oriented synthesis of small-molecule hybrids", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 44, no. 15, 2005, pages 2249 - 2252, XP002517187 *
IMRE FEJES ET AL: "2-Oxoindolin-3-ylidene derivatives as 2Pi components in 1,3-dipolar cycloadditions of azomethine ylides", TETRAHEDRON, vol. 57, no. 6, 2001, pages 1129 - 1137, XP004316545, ISSN: 0040-4020 *
MICHAEL M.-C. LO ET AL: "A library of spirooxindoles based on a stereoselective three-component coupling reaction", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 126, no. 49, 2004, pages 16077 - 16086, XP002517186 *
MIKLOS NYERGES ET AL: "2-Oxoindolin-3-ylidene derivatives as 2Pi components in 1,3-dipolar cycloadditions of azomethine ylides", SYNLETT, no. 1, 1999, pages 111 - 113, XP002517184 *
PAUL R. SEBAHAR AND ROBERT M. WILLIAMS: "The synthesis of spirooxindole pyrrolidines via an asymmetric azomethine ylide [1,3]-dipolar cycloaddition reaction", HETEROCYCLES, vol. 58, 2002, pages 563 - 575, XP001539206 *

Also Published As

Publication number Publication date
WO2008144507A2 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
MX2009006627A (en) Quinazolines for pdk1 inhibition.
CL2012003680A1 (en) Compounds derived from (1,8) 2,4 diaryl naphthyridines substituted kinase inhibitors; its procedure for obtaining; pharmaceutical composition; and its use for the treatment and / or prevention of cancer, tumor, malignant tumors, among others; Pharmaceutical kit
MY152948A (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
WO2009011850A3 (en) Novel therapeutic compounds
WO2007127010A3 (en) Diarylthiohydantoin compounds
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
MY178660A (en) Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2008085794A3 (en) Methods and compositions related to clot binding compounds
PL1951729T3 (en) Oxygen linked pyrimidine derivatives
EP2224919A4 (en) Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
MX2009012271A (en) Rna antagonist compounds for the modulation of her3.
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
WO2007146957A3 (en) Ror1 as a therapeutic target for lung cancer
MX2010003269A (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase.
MX349550B (en) 1, 7 - diazacarbazoles and their use in the treatment of cancer.
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
MX2013002155A (en) Compounds for treatment of cancer.
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08755695

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08755695

Country of ref document: EP

Kind code of ref document: A2